FDA-Drug2026-04-01Class IIPROCESSING DEFECT

Teva Octreotide Acetate injectable suspension recalled for sterility concerns

OTHERNationwide distribution

Stop using Teva Octreotide Acetate injections

Teva Pharmaceuticals is recalling specific lots of Octreotide Acetate injectable suspension (20 mg) due to quality control issues at the manufacturing facility in Greece. The FDA found deficiencies that could affect sterility—the assurance that the medication is free from harmful bacteria and other microorganisms.

  • Check your medication vial for lot numbers: 4401491, 4401600, 4401603, 4401629 (expiring 9/31/2026) or 4500594, 4500786, 4500920, 4501007, 4501462 (expiring 3/31/2027)
  • If you have an affected lot, contact your pharmacy or prescriber immediately—do not use the medication
  • Ask your doctor or pharmacist for a replacement from a non-recalled lot
Hazard

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Sold states
Nationwide in the USA
Affected count
19,869 Cartons
Manufactured in
400 Interpace Pkwy Bldg A, Parsippany, NJ, United States
Products
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9259-08.

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0405-2026

More Teva Pharmaceuticals USA, Inc recalls

Don't want to check this manually?

We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Get the Sunday Brief